NVAX vs PTGX: fair value comparison
Novavax, Inc. and Protagonist Therapeutics, Inc. · Updated 2026-10-19
NVAX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. PTGX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, NVAX currently ranks higher by quality score.
| NVAX | PTGX | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $11.26 | $128.75 |
| 12-month range | $6.22–$12.82 | $73.98–$158.62 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #86 of 301 Healthcare | #88 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | High | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Mixed |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: NVAX fair value analysis · PTGX fair value analysis